-
公开(公告)号：US08926737B2
公开(公告)日：2015-01-06
申请号：US13131085
申请日：2009-11-26
Applicant: Arnab Chatterjee , Carolus Matthias Anna Maria Mesters , Ronald Jan Schoonebeek , Eri Ito
CPC classification number: B01D53/8603 , B01D53/1487 , B01D2257/306 , B01D2258/06 , C10L3/10
Abstract: The present invention provides a process for purifying natural gas, comprising removing mercaptans from a natural gas stream by a combination of an amine-based separation unit and a selective oxidation unit to obtain a purified natural gas stream, wherein at least part of the mercaptans are converted into at least elemental sulphur in the selective oxidation unit by selective catalytic oxidation.
Abstract translation: 本发明提供天然气净化方法，其包括通过胺基分离单元和选择性氧化单元的组合从天然气流中除去硫醇以获得纯化天然气流，其中至少部分硫醇为 通过选择性催化氧化在选择性氧化单元中转化为至少元素硫。
-
公开(公告)号：US08153671B2
公开(公告)日：2012-04-10
申请号：US11995683
申请日：2006-07-14
Applicant: Phillip B. Alper , Thomas Marsilje , Arnab Chatterjee , Wenshuo Lu , Daniel Mutnick , Michael Roberts , Yun He
Inventor： Phillip B. Alper , Thomas Marsilje , Arnab Chatterjee , Wenshuo Lu , Daniel Mutnick , Michael Roberts , Yun He
IPC: A61K31/404 , C07D487/02
CPC classification number: C08J7/04 , C07D209/80 , C07D209/94 , C07D401/04 , C07D403/04 , C07D413/04 , C07D417/04 , C07D491/04 , C07D495/04 , C08J7/045 , C08J2369/00
Abstract: The invention provides a novel class of compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated TPO activity, particularly diseases or disorders that involve thrombocytopenia.
Abstract translation: 本发明提供了一类新颖的化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与异常或失调的TPO活性相关的疾病或病症的方法，特别是涉及血小板减少症的疾病或病症。
-
公开(公告)号：US07384970B2
公开(公告)日：2008-06-10
申请号：US10807613
申请日：2004-03-23
Applicant: Hong Liu , Phil Alper , Arnab Chatterjee , David Tully , Badry Bursulaya , David Woodmansee , Robert Epple , Jennifer Leslie Harris , Jun Li
Inventor： Hong Liu , Phil Alper , Arnab Chatterjee , David Tully , Badry Bursulaya , David Woodmansee , Robert Epple , Jennifer Leslie Harris , Jun Li
IPC: A61K31/4045 , C07D209/08
CPC classification number: C07D405/12 , C07C237/22 , C07C237/24 , C07C257/18 , C07C311/19 , C07C311/29 , C07C2601/14 , C07D207/12 , C07D207/24 , C07D209/08 , C07D209/42 , C07D211/60 , C07D213/71 , C07D231/14 , C07D257/04 , C07D261/18 , C07D271/10 , C07D307/20 , C07D307/24 , C07D307/68 , C07D309/08 , C07D311/22 , C07D333/40 , C07D335/02 , C07D401/12 , C07D401/14 , C07D403/06 , C07D403/12 , C07D405/14 , C07D409/12 , C07D409/14 , C07D413/06 , C07D413/12 , C07D413/14 , C07D417/12 , C07D417/14
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Abstract translation: 本发明提供了选择性抑制组织蛋白酶S的化合物，组合物和方法。在优选的方面，组织蛋白酶S在至少一种其它组织蛋白酶同功酶的存在下被选择性地抑制。 本发明还提供了通过选择性抑制组织蛋白酶S来治疗受试者的疾病状态的方法。
-
公开(公告)号：US20070275906A1
公开(公告)日：2007-11-29
申请号：US11749430
申请日：2007-05-16
Applicant: David Tully , Arnab Chatterjee , Agnes Vidal , Hank Petrassi , Zhiwei Wang , Badry Bursulaya , Glen Spraggon
Inventor： David Tully , Arnab Chatterjee , Agnes Vidal , Hank Petrassi , Zhiwei Wang , Badry Bursulaya , Glen Spraggon
IPC: A61K38/04 , A61K31/454 , C07K5/04
CPC classification number: C07D417/14 , C07D413/12 , C07D413/14 , C07D417/12 , C07K5/0806 , C07K5/0808 , C07K5/0812 , C07K5/0821 , C07K5/0827
Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating channel activating proteases, and methods for, using such compounds to treat, ameliorate or prevent a condition associated with a channel activating protease, including but not limited to prostasin, PRSS22, TMPRSS11 (e.g., TMPRSS11B, TMPRSS11E), TMPRSS2, TMPRSS3, TMPRSS4 (MTSP-2), matriptase (MTSP-1), CAP2, CAP3, trypsin, cathepsin A, or neutrophil elastase.
Abstract translation: 本发明提供了可用于调节通道活化蛋白酶的化合物及其药物组合物，以及使用这些化合物治疗，改善或预防与通道活化蛋白酶（包括但不限于前列腺素PRSS22，TMPRSS11）相关的病症的方法 （例如TMPRSS11B，TMPRSS11E），TMPRSS2，TMPRSS3，TMPRSS4（MTSP-2），matriptase（MTSP-1），CAP2，CAP3，胰蛋白酶，组织蛋白酶A或嗜中性粒细胞弹性蛋白酶。
-
公开(公告)号：US07109243B2
公开(公告)日：2006-09-19
申请号：US10807612
申请日：2004-03-23
Applicant: Hong Liu , David Tully , Robert Epple , Badry Bursulaya , Jennifer Williams , Arnab Chatterjee , Jennifer Leslie Harris , Jun Li
Inventor： Hong Liu , David Tully , Robert Epple , Badry Bursulaya , Jennifer Williams , Arnab Chatterjee , Jennifer Leslie Harris , Jun Li
IPC: A01N47/28
CPC classification number: C07D307/68 , C07C237/14 , C07C237/20 , C07C255/57 , C07C275/28 , C07C275/30 , C07C275/42 , C07C2601/14 , C07D213/56 , C07D213/64 , C07D237/24 , C07D239/52 , C07D277/56 , C07D333/38
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme (e.g., cathespin K). The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
Abstract translation: 本发明提供用于选择性抑制组织蛋白酶S的化合物，组合物和方法。在优选的方面，组织蛋白酶S在至少一种其它组织蛋白酶同功酶（例如cathespin K）的存在下被选择性地抑制。 本发明还提供了通过选择性抑制组织蛋白酶S来治疗受试者的疾病状态的方法。
-
Patent Agency Ranking
公开(公告)号：US20050049244A1
公开(公告)日：2005-03-03
申请号：US10868459
申请日：2004-06-10
Applicant: Hong Liu , David Tully , Phillip Alper , Robert Epple , Arnab Chatterjee , Michael Roberts
Inventor： Hong Liu , David Tully , Phillip Alper , Robert Epple , Arnab Chatterjee , Michael Roberts
IPC: A61K20060101 , A61K31/421 , A61K31/422 , A61K31/423 , A61K31/426 , A61K31/427 , A61K31/428 , A61K31/47 , A61K31/495 , A61K31/4965 , A61K31/537 , A61K31/54 , C07D277/82 , C07D401/12 , C07D403/12 , C07D413/12 , C07D417/12
CPC classification number: C07D327/04 , C07D277/82 , C07D403/12 , C07D405/12 , C07D409/12
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S.
-
公开(公告)号：US20110274604A1
公开(公告)日：2011-11-10
申请号：US13131130
申请日：2008-11-26
IPC: B01D53/52
CPC classification number: B01D53/8612 , B01D2251/10 , B01D2255/20707 , B01D2256/16 , B01D2256/24 , B01D2257/304 , C01B17/0469
Abstract: The present invention provides a process for the selective oxidation of hydrogen sulphide contained in a hydrogen sulphide-containing hydrocarbon feed gas to elemental sulphur. The hydrogen sulphide-containing hydrocarbon feed gas and a sulphur dioxide-containing gas are supplied to a reaction zone containing a TiO2-comprising catalyst, wherein elemental sulphur and a gaseous stream depleted in hydrogen sulphide are formed. The gas feeds are contacted with the TiO2 containing catalyst at elevated pressure and at a temperature in the range of from 120 and below 160° C., under such conditions that the elemental sulphur formed is essentially in liquid form. At least part of the sulphur dioxide-containing gas is obtained by combusting elemental sulphur to obtain a gaseous mixture of sulphur dioxide and nitrogen and then concentrating the gaseous mixture to provide the sulphur dioxide-containing gas.
Abstract translation: 本发明提供了将含硫化氢的烃进料气体中所含的硫化氢选择性氧化成元素硫的方法。 将含硫化氢的烃进料气体和含二氧化硫的气体供应到含有TiO 2的催化剂的反应区，其中形成元素硫和贫硫化氢气体。 气体进料在升高的压力下和在120℃和低于160℃的温度下，在形成的元素硫基本上是液体形式的条件下与含TiO 2的催化剂接触。 通过燃烧元素硫以获得二氧化硫和氮的气体混合物，然后浓缩气体混合物以提供含二氧化硫的气体，获得至少部分含二氧化硫的气体。
-
公开(公告)号：US20110265380A1
公开(公告)日：2011-11-03
申请号：US13131085
申请日：2009-11-26
Applicant: Arnab Chatterjee , Carolus Matthias Anna Maria Mesters , Ronald Jan Schoonebeek , Eri Ito
IPC: C10L3/10
CPC classification number: B01D53/8603 , B01D53/1487 , B01D2257/306 , B01D2258/06 , C10L3/10
Abstract: The present invention provides a process for purifying natural gas, comprising removing mercaptans from a natural gas stream by a combination of an amine-based separation unit and a selective oxidation unit to obtain a purified natural gas stream, wherein at least part of the mercaptans are converted into at least elemental sulphur in the selective oxidation unit by selective catalytic oxidation.
Abstract translation: 本发明提供天然气净化方法，其包括通过胺基分离单元和选择性氧化单元的组合从天然气流中除去硫醇以获得纯化天然气流，其中至少部分硫醇为 通过选择性催化氧化在选择性氧化单元中转化为至少元素硫。
-
公开(公告)号：US20110245243A1
公开(公告)日：2011-10-06
申请号：US13161555
申请日：2011-06-16
Applicant: Hong LIU , David C. TULLY , Arnab CHATTERJEE , Phillip B. ALPER , David H. WOODMANSEE , Daniel MUTNICK
Inventor： Hong LIU , David C. TULLY , Arnab CHATTERJEE , Phillip B. ALPER , David H. WOODMANSEE , Daniel MUTNICK
IPC: A61K31/5377 , A61K31/5375 , A61K31/454 , A61K31/4245 , A61K31/423 , C07D413/12 , C07D265/30 , A61P43/00 , C07D417/12
CPC classification number: C07D263/56 , C07D211/66 , C07D273/02 , C07D277/64 , C07D295/185 , C07D307/30
Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of Cathepsin S.
Abstract translation: 本发明提供化合物，包含这些化合物的药物组合物和使用这些化合物治疗或预防与组织蛋白酶S活性相关的疾病或病症的方法。
-
公开(公告)号：US20100204200A1
公开(公告)日：2010-08-12
申请号：US12764772
申请日：2010-04-21
Applicant: Hong Liu , Arnab Chatterjee , David C. Tully , Phillip Alper , Badry Bursulaya , Jianhua Guo , David H. Woodmansee , Daniel Mutnick , Donald S. Karanewsky , Yun He
Inventor： Hong Liu , Arnab Chatterjee , David C. Tully , Phillip Alper , Badry Bursulaya , Jianhua Guo , David H. Woodmansee , Daniel Mutnick , Donald S. Karanewsky , Yun He
IPC: A61K31/5377 , C07D413/12 , C07D295/145 , C07D413/14 , C07C245/00 , C07D401/12 , C07D403/12 , A61K31/5375 , A61K31/54 , A61K31/496 , A61K31/404
CPC classification number: C07D209/08 , C07D261/14 , C07D295/18 , C07D295/20
Abstract: The present invention provides compounds, compositions and methods for the selective inhibition of cathepsin S. In a preferred aspect, cathepsin S is selectively inhibited in the presence of at least one other cathepsin isozyme. The present invention also provides methods for treating a disease state in a subject by selectively inhibiting cathepsin S. More particularly, the present invention provides compounds having Formula 1: wherein Q is an optionally substituted azetidinyl, pyrrolidinyl, piperidyl, and indolinyl; or Q is NR25R26; and A, R5, R6, R7, R8, R9, R25, R26 and Ar are substituents.
Abstract translation: 本发明提供了选择性抑制组织蛋白酶S的化合物，组合物和方法。在优选的方面，组织蛋白酶S在至少一种其它组织蛋白酶同功酶的存在下被选择性地抑制。 本发明还提供了通过选择性抑制组织蛋白酶S来治疗受试者的疾病状态的方法。更具体地，本发明提供了具有式1的化合物：其中Q是任选取代的氮杂环丁烷基，吡咯烷基，哌啶基和二氢吲哚基; 或Q为NR25R26; A，R 5，R 6，R 7，R 8，R 9，R 25，R 26和Ar为取代基。
-
-
-
-
-
-
-
-
-
Search Results
26
records
(took 0.035 seconds)
